40Evidence A

If you are diagnosed with osteoporosis, or have fractured from a minor fall, ask a doctor for osteoporosis medication and keep taking it—do not treat calcium supplements as a substitute

For postmenopausal women who have already been diagnosed with osteoporosis or have experienced fractures, taking alendronate can reduce the risk of hip fractures by approximately half. Symptomatic spinal fractures are reduced by more than half. For elderly patients who begin receiving an annual infusion of medication after surgery for a hip fracture, the rate of subsequent fractures within two years is reduced by approximately 35%. Supplementing with calcium alone cannot replace these medications.

Cost

Prescription required;

Benefit

Fragility fracture means a fracture from minor trauma or everyday activity. The Chinese Medical Association 20…

Cost

Prescription required; use continues for years. Common options include once-weekly oral drugs and once-yearly infusions. Bone density should be rechecked yearly at first, then every 1 to 2 years once stable. The hard part is continuing when you feel fine.

Benefit

Fragility fracture means a fracture from minor trauma or everyday activity. The Chinese Medical Association 2017 guideline lists three groups for treatment: prior fragility fracture of spine or hip; bone density T-score −2.5 or lower regardless of prior fracture; or low bone mass plus fragility fracture of wrist, upper arm, or pelvis, or high calculated fracture risk. The guideline states: "There is currently insufficient evidence that calcium supplementation alone can replace other anti-osteoporosis drug therapy." Cochrane's 2025 update on alendronate in postmenopausal women with osteoporosis or prior fracture found hip fractures about 51% lower in the treated group (RR 0.49, 95% CI 0.25 to 0.96) and symptomatic vertebral fractures about 55% lower (RR 0.45, 95% CI 0.28 to 0.73). The HORIZON trial enrolled 2,127 people mean age 74.5 after hip-fracture surgery; yearly zoledronic acid starting within 90 days post-op, median follow-up 1.9 years. New fractures fell from 13.9% to 8.6% (about 35% relative reduction). Death fell from 13.3% to 9.6% (about 28% relative reduction). The guideline notes about 20% of people die from complications within one year after hip fracture. In the 2017–2018 national survey, only 1.4% of women and 0.3% of men with diagnosed osteoporosis or prior fracture were on medication (China).

Original sources

中华医学会骨质疏松和骨矿盐疾病分会 (2017). 原发性骨质疏松症诊疗指南(2017). 中华骨质疏松和骨矿盐疾病杂志, 10(5), 413-443(表 10 抗骨质疏松症药物治疗适应证;钙剂一节;疗效监测一节). https://html.rhhz.net/GUSS/html/cc825127-29a3-47c1-9a95-7a212fdcce55.htm ; Wells GA, Hsieh SC, Peterson J, et al. (2025). Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001155.pub3 ; Lyles KW, Colón-Emeric CS, Magaziner JS, et al. (2007). Zoledronic acid and clinical fractures and mortality after hip fracture. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa074941 ; Cummings SR, Lui LY, Eastell R, Allen IE (2019). Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2019.2779 ; Kahwati LC, Kistler CE, Booth G, et al. (2025). Screening for Osteoporosis to Prevent Fractures: A Systematic Evidence Review for the US Preventive Services Task Force. JAMA. https://doi.org/10.1001/jama.2024.21653 ; Wang L, Yu W, Yin X, et al. (2021). Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2021.21106

Open source link
Book note

Controversy: a meta-analysis combining 38 trials found no reduction in all-cause mortality with these drugs (RR 0.98, 95% CI 0.91 to 1.05). The result for zoledronic acid alone was also not statistically significant (RR 0.88, 95% CI 0.68 to 1.13). The authors concluded that these drugs should be used only to reduce fractures. The certainty of those Cochrane estimates was also rated low to moderate. In women who had not yet had a fracture and whose fracture risk was relatively low, alendronate showed no clear effect on hip fractures (RR 0.76, 95% CI 0.43 to 1.32). Trials lasting a few years cannot fully capture rare adverse effects such as osteonecrosis of the jaw and atypical femoral fractures, so attend follow-up appointments on time and do not increase or stop medication on your own. Injections suit some people, while oral treatment suits others; a doctor should choose which. For diagnosing osteoporosis, see item 39 (bone density testing). Menopausal hormone therapy can also reduce fractures, but is generally considered only when other drugs are unsuitable. For using hormones for hot flashes and night sweats, see Section 2, item 43 (seek assessment for hormone therapy for hot flashes around menopause). The main beneficiary is you, and your parents may also benefit.

My note